Cereno Scientific reports acquired warrants within the framework of the incentive programs
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that Board member Jeppe Øvlesen and a current employee in the company have acquired warrants within the framework of the company’s incentive programs as resolved at the extraordinary general meeting held on November 7, 2023.The Board member who has signed warrants of series 2023/2026:3 within the framework of the incentive program is as follows: · Jeppe Øvlesen, Member, 1 000 000 warrants The person who has acquired warrants of series